Innate Pharma S.A. (EPA:IPH)

Market Cap	115.22M -36.5%
Revenue (ttm)	9.01M -55.2%
Net Income	-49.18M
EPS	-0.55
Shares Out	93.83M
PE Ratio	n/a
Forward PE	1.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,622
Average Volume	363,171
Open	1.258
Previous Close	1.250
Day's Range	1.214 - 1.258
52-Week Range	1.030 - 2.065
Beta	0.81
RSI	48.42
Earnings Date	Sep 17, 2026

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 174
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPH

Financial Performance

In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.